In vitro generation of cytotoxic cells specific for human minor histocompatibility antigens by lymphocytes from a normal donor potentially primed during pregnancy by unknown
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Minor histocompatibility antigens  are defined as antigens  that  elicit tissue-graft 
rejection in the absence of differences at the major histocompatibility complex (MHC) 
(1). Analysis of T  cell responses to minor antigens is potentially informative for two 
reasons:  (a) as one model system in which to analyze the basic mechanisms of T  cell 
responses, and  (b)  as an in vitro model of immune responses that  occur in clinical 
transplant  recipients  of tissue  from  an  MHC-matched  allogeneic  donor.  T  cell 
recognition of  minor histocompatibility antigens normally requires identity of a major 
histocompatibility antigen between responder and stimulator and an in vivo priming 
of the responding individual (2, 3). The best characterized human minor antigen is 
designated  H-Y,  the  male-associated antigens.  Goulmy and  colleagues  (4)  first  de- 
scribed  human  cell-mediated  cytoxicity specific for H-Y in  the  blood of a  female 
patient with aplastic anemia who had rejected a bone marrow transplant from a male 
HLA-identical sibling. Subsequent studies have shown that multiple transfusions are 
sufficient to prime for cellular responses to the H-Y antigen. Several individuals have 
been found to have HLA-A2-restricted H-Y-specific cytotoxic effectors, and at least 
one donor was also found to have a subset of HLA-B7-restricted H-Y-specific cytotoxic 
effectors (5). Minor histocompatibility antigens different from H-Y were first described 
by Parkman et al.  (6);  specific cytotoxic T  lymphocytes (CTL) were derived from 
patients with aplastic anemia, who had rejected bone marrow transplants from HLA- 
identical siblings. Elkins et al. (7) described a patient whose lymphocytes were primed 
to recognize an HLA-B7-restricted minor antigen. Similar to the circumstances in H- 
Y  priming,  this  patient  had  received  repeated  transfusions  from  HLA-identical 
siblings (some of whose cells expressed this minor antigen). 
The present study reports and analyzes HLA-restricted cell-mediated lympholysis 
(CML) against a human minor antigen(s) that can be readily generated in vitro from 
the blood of a normal female. Since she is a  multiparous female whose children are 
virtually HLA identical to her but express the minor antigen, it is plausible that her 
response reflects in vivo priming during pregnancy. 
Materials and Methods 
Human peripheral blood mononuclear cells were obtained by batch leukapheresis, separated 
by flotation on Ficoll-Hypaque, and cryopreserved as previously described (8).  Plasma from six 
or more male donors was pooled, frozen in aliquots at -20°C, and used as the normal human 
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TAI~LE I 
Cytotoxicity Generated between Cells  from HLA-A, -B, -C-Identical Donors 
2173 
Eff~ton  Targets  (Percent cytotoxicity) 
Responder  HMI*  Stimulator  HM1  B17  F2  H7  H9  K4  MI4  W7 
SI 1  -  H9  - 
FI  -  BI7  -  15.1 
W7  +  H9  - 
F2  +  B17  -  13.6 
W7  +  MI4  - 
PMI  +  M14  -- 
H7  +  K4  - 
F2  +  K4  - 
W7  +  K4  - 
K4  -  H7  +  5.7 
K4  -  W7  +  6.8 
H9  -  W7  +  48.0 
B17  -  F2  +  12.2 
K4  -  F2  +  2.4 
F2  +  W7  +  12.3 
FC4  FR4  59.4  50.6  57.3  46.0  47.4  41.7  52.4 
7.2 
3.7 
2.4 
12.8 
8.8 
6.1 
6.7 
FC4:  HLA-A2,2, -B7,7, -C-, -- FR4:  HLA-AI,I,  -B8,8, -C-, -. All other donors  type as HLA-AI,2,  -B7,8, 
-C7, -. 
*  Determined  by whether  target  cells from  these donors  were lysed by  H9/W7. 
plasma pool..Serotyping for HLA-A,  -B,  -C,  and  -DR  was  kindly performed by  Dr.  Rene 
Duquesnoy, Blood Center of Southeastern Wisconsin, Milwaukee, WI. 
CTL  were  generated  as  previously described  (9).  Briefly,  9  ×  10  s  responding cells were 
cultured for 10 d with 3 ×  106 2,000-rad-irradiated stimulator cells in a 25-cm  2 tissue culture 
flask. To generate secondary effectors  primary cultures were harvested after  10 d and either 
cryopreserved  or  restimulated  immediately.  3  X  10  s  primed  cells  (fresh  or  thawed  after 
cryopreservation) were restimulated with 9 X  l0  s 2,000-rad-irradiated stimulator cells in 8 ml 
culture medium supplemented with 1.5 ml heat-inactivated human plasma, and harvested after 
4d. 
Cytotoxicity was determined in a standard 4-h 5XCr-release assay (8)  using 1 x  104 phyto- 
hemagglutinin (PHA)-stimulated target cells and effector to target cell ratios of 40:1, 15:1, and 
4:1. CML assays were performed in triplicate and percent specific lysis was calculated as [(mean 
counts per minute, experimental -  mean counts per minute, media)/(mean counts per minute, 
detergent -  mean counts per minute, media)] X  100. 
Results and Discussion 
Detection of a  CML  Target Antigen  by a  Unique Responder]Stimulator Combination.  As 
part  of a  systematic analysis  of histocompatibility antigens  that  differ between  12 
donors completely matched for the serologically defined HLA-A, -B, and -C antigens, 
mixed lymphocyte cultures  (MLC)  were generated between many combinations of 
these donors, restimulated in secondary MLC, and the lymphocytes tested for CTL 
activity with target cells from the donor used as stimulator. CTL FC4/FR4, directed 
against  HLA-A1 and -BS, was used as control to show comparable lysability of the 
different target cells (Table I). Strong eytotoxieity (>20% lysis)  on PHA-stimulated 
lymphoblasts was seen in only one combination: donor H9 anti-donor W7. Detection 
of this  antigen  by CML  seemed to require secondary restimulation, because little 
cytotoxicity was  seen  after  primary  stimulation  (data  not  shown).  To  maximize 
reproducibility in subsequent studies of the specificity of this cytotoxic activity, large 
batches  of primed  cells  were  frozen  after primary  stimulation,  and  were  used  as 2174  TEKOLF  AND  SHAW  BRIEF  DEFINITIVE  REPORT 
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FIe.  1.  Lysis  of HLA-B7-positive  and HLA-B7-negative  donors by H9/W7, expressed as relative 
percent eytotoxieity compared with lysis of W7 (100%). Lysis of W7 cells in the four experiments 
ranged between 45 and 65% specific lysis. (A) Donor H9 (HLA-AI,2, -B7,8, -C7,-, -DR2,3, SB1,2) 
Donor FH3 (HLA-A1,2, -B7,8, -C7,-, -DR2,3, SB1,4) ~  Donor FH4 (HLA-1,2, -B7,8, -C7,-, 
-DR2,3, SB 1,2) (O) Donor W 1 (HLA-A23,24,  -B44,-, -C4,-, -DRT,-) (A) Donor W7 (HLA-  1,2, B7,8, 
-C7,-, -DR2,3, SB 1,4) (0) all other unrelated normal donors. 
cytotoxic effectors after thawing and secondary restimulation with W7 cells. 
Fig.  1 summarizes the results of four experiments testing H9/W7 effectors on panels 
of target cells from unrelated donors. The pattern of lysis was clearly bimodal, which 
indicates that these effectors were recognizing predominantly the presence or absence 
of a  single antigen  or group of genetically associated antigens  in the population  of 
donors. Target cells from 17 of 35 HLA-B7-positive donors were lysed, while only 1 
of 40 B7-negative donors' cells was lysed. Thus, with a  single exception, the antigen 
was detected only on B7-positive cells.  The single exception  is donor W1, with  the 
serologieally defined phenotype of HLA-A23, -24, -Bw44, -. Family studies of the only 
available family member failed to distinguish whether this reflects homozygosity for 
Bw44 or the presence of a serologically undefined B locus antigen. 
Family Studies Indicate Control by Gene(s) Independent of HLA.  The pattern  of lysis 
observed in the population was consistent with at least three possible specificities of 
the CTL: (a) for a molecular variation in the B7 molecule that is not yet serologically 
defined;  (b) for the product of an allele of another HLA-linked gene in strong positive 
linkage disequilibrium with the HLA-B7 allele; or (c) for a human 'minor' histocom- 
patibility antigen recognized in conjunction with an HLA antigen highly associated 
with B7.  Studies  of three generations of family B  (Table II) prove that  the antigen 
recognized by H9/W7 is controlled by at least one gene distinct from B7. The donors 
in  the  family whose cells express the cytotoxic target  antigen  are those  that  have 
inherited the 'a' haplotype, which encodes HLA-B 7. However, one of the six members 
(FB12)  who has inherited this haplotype does not express the antigen recognized by 
the  CTL  H9/W7;  since  the  typing  indicates  clearly  that  FB12  inherited  the  B7 
haplotype from his mother FB4, failure of his cells to express the CTL antigen must 
indicate that the B7 gene per se is not sufficient for expression of the CTL antigen. 
Furthermore, these data make hypothesis b unlikely; there has been no recombination 
on  the  B7  haplotype between  HLA-Aw24  and  DR4,  so  the  postulated  HLA-B7- TEKOLF  AND  SHAW  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Family Studies of the Antigen Detected by CTL H9/ W7 
Family B 
FB2  FB 1 
a]b  c/d 
81.9"  9.2 
FB5  FB7  FB6  FB 11  FB3  FB8 
b/d  a/d  b/c  ba/c  a/c  a/c 
10.1  49.2  6.7  2.0  63.1  58.3 
FB4  FB21 
a/e  e/f 
61.1'  ND  ~ 
I 
FB12 
a/e 
10.8 
a: Aw24,Cw-,B7,DR4,SB  1. 
b: A25,Cw-,B  15,DR4,SB4. 
c: Aw31  ,Cw3,Bw40,DR4,SB-. 
d: Aw33,Cw3,B  17,DR5,SB4. 
b/a: A25,Cw-,B  15,DR4/SB 1. 
e: A2, Cw5,Bw44,DRw6,SB?. 
f: not determined. 
Family W 
FW 1  FW2 
a/b  c/d 
56.7  4.1 
FW3(=W7)  FW4  FW5 
a/d  a/c  h/c 
50. [  51.8  46.0 
a: A2,CwT,B7,DR2 
b: Aw30,Cw5,B  18,DR3 
e: A3,Cw7,B7,DR2 
d: A 1,Cw7,B8,DR3 
* Percent cytotoxicity. 
* Percent specific lysis by an HLA-B7-speeific C'TL combination was 37.4% for FB4 and 
36.2% for FB12. 
Not determined. 
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associated allele would have to be of a gene outside this region, and therefore unlikely 
to show such extraordinarily strong linkage disquilibrium with B7. 
The results on the second family (W), although less conclusive, are most consistent 
with minor antigen recognition (Table II). In this family, both parents are positive for 
B7,  but  only  the  father expresses  the  antigen  recognized  by  H9/W7.  If the  target 
antigen were related only to expression of a particular structurally distinct subset of 
the B7 molecule, then only the children who inherited the B7 from the father ought 
to express the antigen recognized by H9/W7. Instead, all children, including one who 
inherited B7 from the mother and not from the father (FW5), express the antigen. A 
plausible  interpretation  of  this  data  is  that  although  the  mother  expressed  an 
appropriate  B7, she lacked the relevant  allele of the minor antigen;  FW5 expresses 
the full antigenic  complex since he inherited the B7  gene from his mother and the 
minor  antigen  from  his  father.  There  is  an  alternate  explanation:  that  the  CTL 
antigen that is recognized on the father's cells is encoded by genes on both his HLA- 
B7  and -B18  haplotypes;  however, it  is statistically  improbable  (P ~1/40)  that  his 2176  TEKOLF AND SHAW  BRIEF  DEFINITIVE REPORT 
A30-B 18 haplotype should encode the antigen when most B7-negative haplotypes in 
the population do not.  Data  from these two families suggest  that  there is  another 
gene, provisionally designated HM 1 for human minor 1, that controls the expression 
of the complete antigen. This antigen is not identical to the H-Y antigen because it 
is expressed on cells of female donors as well. The phenotype frequency for HM1, 
calculated  from the  phenotype frequency among HLA-B7-positive donors  (17/35) 
(Fig.  1), is ~50%, which implies a  gene frequency of ~30%, if the gene is expressed 
codominantly. 
Evidence for Possible In  Vivo Priming During Pregnancy.  The combination H9/W7  is 
unusual  in  its  ability to recognize HM 1.  As can be seen from Table I, four other 
combinations of HMl-negative cells against HM 1-positive cells, e.g., B 17/F2 or K2/ 
W7, do not detect HM1. Furthermore, other potential minor antigen differences are 
not recognized strongly in any of the 14 other combinations of HLA-matched donors. 
The lower level of lysis  (<20%), seen in many combinations, is consistent with Ia- 
specific kill on the PHA-stimulated targets (10). Is the detection of a minor histocom- 
patibility  antigen  by  the  CTL  response  H9  anti-W7  really  due  to  an  unusual 
responsiveness of H9 or perhaps due to a  uniqueness of cells from donor W7? Two 
additional  data argue for the former. First,  W7  did not stimulate  cells from other 
donors against  minor histocompatibility antigens  (Table I).  Second, although H9/ 
W7  preferentially recognized only one antigen,  the  relative differences within  the 
group of HLA-B7-negative donors suggest further complexity (Fig. 1). Indeed, another 
donor was identified, whose cells stimulated cells from H9 against at least two other 
minor histocompatibility antigens (manuscript in preparation). Thus, H9 is unique in 
the ability of her cells to recognize multiple minor histocompatibility antigens. 
Studies of minor histocompatibility antigens in mice indicate that detection of these 
antigens normally requires both an initial in vivo priming and H-2 identity between 
responder and stimulator during priming. We therefore investigated whether an in 
vivo priming of donor H9  could account  for the  donor's unusual  reaction against 
minor histocompatibility antigens.  As  H9 never received any blood transfusions or 
organ transplants, pregnancy would have been the only known allogeneic exposure. 
It has already been demonstrated, by detection of Y chromosome-containing lympho- 
cytes in the blood of mothers with male fetuses, that an exchange of small amounts of 
white cells can occur (11).  Theoretically it is likely that these cells are removed from 
the  maternal  circulation  quite  rapidly  by  humoral  and  cellular  responses  against 
antigens  controlled by  the  paternal  HLA  haplotype of the  fetal  cells.  Studies  of 
available members of H9's family revealed the postulated conditions for an in vivo 
priming against minor histoeompatibility antigens (Table I). Both children are HLA- 
A, -B, -C, and -DR identical with their mother. One child (FH3) is SB different and 
expresses the HM1  target antigen. The other child is SB identical with her mother 
and does not express HM 1. These data not only prove that one of the children carries 
the relevant antigen necessary for a priming during pregnancy but also show a virtual 
HLA  identity  between  mother  and  children,  which  may  have  provided  optimal 
conditions for priming against  minor histocompatibility antigens during pregnancy. 
No other unusual features of H9's pregnancies could be identified. 
Although minor histocompatibility antigens are thought to play an important role 
in  transplantation  biology, our knowledge about  these antigens  in  humans  is  very 
limited. Cells from donors like the one described in this study, i.e., in whom a priming TEKOLF AND SHAW  BRIEF  DEFINITIVE REPORT  2177 
against  minor histocompatibility antigens has occurred, will facilitate  identification 
of "immunodominant"  minor  histocompatibility  antigens  and  investigation  of the 
biological role of these antigens. 
Summary 
A  normal female donor (Hg)  is described,  whose cells generate strong cytotoxicity 
against  a  human  minor  histocompatibility  antigen  in  vitro.  These  cytotoxic  T 
lymphocytes are generated after secondary restimulation with cells from an HLA-A, 
-B, -(2, and -DR-matched donor and are HLA restricted  (HLA-BT). No other donor 
could be identified whose cells responded to this antigen. The two children of donor 
H9 are virtually HLA identical to her and one of the children expresses the relevant 
minor  histocompatibility  antigen.  These  data  suggest  that  priming  in  vivo  during 
pregnancy has facilitated cytotoxic T  cell response to human minor histocompatibility 
antigens in vitro. 
Dedicated to Professor W. Docile on the occasion of his 60th birthday. 
Received  for publication 28 February 1983 and in revised  form 5 April 1983. 
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